Olfr482, an integral member of the olfactory receptor gene family, orchestrates the perception of smell by interacting with odorant molecules in the nasal environment. This receptor, characterized by a 7-transmembrane domain structure typical of G-protein-coupled receptors (GPCRs), is encoded by single coding-exon genes. The GPCR architecture of Olfr482 positions it within a family that includes neurotransmitter and hormone receptors, emphasizing its significance in the intricate process of odorant signal transduction. The elaborate nomenclature assigned to olfactory receptor genes and proteins for this organism underscores the unique and independent nature of their function compared to other organisms. The central function of Olfr482 lies in its role as a molecular gatekeeper for the initiation of neuronal responses triggered by odorant signals. The receptor's interaction with odorant molecules activates G protein-mediated transduction, culminating in the perception of a specific smell. The sheer magnitude of the olfactory receptor gene family, with Olfr482 as its notable member, underscores the importance of these proteins in facilitating a nuanced olfactory experience. This family's involvement in the recognition and transduction of odorant signals highlights the complexity and precision required for the olfactory system to discern and interpret a diverse range of scents.
Inhibition of Olfr482 involves a spectrum of mechanisms aimed at impeding its fundamental functions in odorant signal transduction and neuronal response initiation. Direct inhibition strategies include the binding of specific chemicals to the transmembrane domain of Olfr482, disrupting its conformation and hindering the proper recognition of odorant molecules. Other inhibitors interfere with the G protein-mediated transduction process, blocking the downstream signaling events triggered by Olfr482 activation. Indirect inhibition mechanisms focus on the modulation of signaling pathways associated with Olfr482 or the regulation of gene expression within the olfactory receptor gene family. These strategies influence the receptor's function by altering the broader cellular context in which Olfr482 operates, showcasing the multifaceted approaches to inhibiting this critical olfactory receptor. The presented inhibitors collectively reflect the intricate interplay between Olfr482 and its cellular environment. By targeting specific aspects of the receptor's structure or signaling pathways, these inhibitors provide valuable insights into the underlying mechanisms of olfactory perception. Understanding the diverse means of inhibiting Olfr482 contributes to unraveling the complexities of the olfactory system at the molecular level, offering potential avenues for further exploration in the realm of sensory biology.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor targeting the PI3K/AKT pathway. Disrupts Olfr482 indirectly by inhibiting downstream signaling cascades, perturbing the intracellular environment crucial for Olfr482 activation and expression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
MAPK inhibitor disrupting the MAPK pathway involved in Olfr482 regulation. Interferes with the phosphorylation events downstream, leading to altered gene expression patterns and consequent inhibition of Olfr482. | ||||||
Paroxetine | 61869-08-7 | sc-507527 | 1 g | $180.00 | ||
GRK inhibitor affecting the desensitization of G protein-coupled receptors, including Olfr482. Disrupts the regulatory feedback loop, prolonging receptor activation and indirectly suppressing Olfr482 expression. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
PKC inhibitor modulating the PKC signaling pathway implicated in Olfr482 regulation. Alters downstream effectors and disrupts the signal transduction, ultimately inhibiting Olfr482 expression through intricate cellular interactions. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
cAMP phosphodiesterase inhibitor influencing cAMP levels, a secondary messenger in Olfr482 signaling. Maintains elevated cAMP, disrupting the normal feedback mechanisms, leading to decreased Olfr482 expression through altered transcriptional and post-translational processes. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $35.00 $115.00 $515.00 | 26 | |
Wnt signaling pathway inhibitor targeting the Wnt signaling pathway linked to Olfr482 regulation. Modulates intracellular events downstream of Wnt, affecting the intricate crosstalk that indirectly influences Olfr482 expression by disrupting the associated molecular network. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Ras/Raf/MEK/ERK pathway inhibitor disrupting the Ras/Raf/MEK/ERK pathway, intricately involved in Olfr482 signaling. Alters the phosphorylation cascade, leading to downstream changes in gene expression and suppression of Olfr482 by interfering with its regulatory network. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
CaMKII inhibitor impacting the calcium signaling pathway crucial for Olfr482 activation. Alters the downstream effectors and disrupts the finely tuned intracellular calcium levels, indirectly inhibiting Olfr482 expression by interfering with the intricate calcium-dependent regulatory mechanisms. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
NF-κB pathway inhibitor targeting the NF-κB pathway associated with Olfr482 regulation. Modulates the nuclear translocation of NF-κB, influencing the transcriptional landscape and indirectly suppressing Olfr482 expression by disrupting the dynamic regulatory interactions within the pathway. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
JAK/STAT signaling inhibitor affecting the Janus kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) pathway. Alters the phosphorylation events downstream, influencing Olfr482 expression by disrupting the intricate signaling cascades associated with JAK/STAT pathway activation. |